Global COVID-19 Current Therapy Market to Reach Billion by 2029, Growing at % CAGR

How Are the key drivers contributing to the expansion of the covid-19 current therapy market?
The COVID-19 pandemic has fueled expansion in the COVID-19 current therapy market. The global pandemic has been recognized by The World Health Organization (WHO). For instance, the WHO, a United Nations agency headquartered in Switzerland, reported that global COVID-19 cases had soared to 581.8 million by August 2022. Since there's no formal drug approval for COVID-19, the call for repurposed drugs that can be used in coronatherapy has increased substantially. There's a drug shortage being experienced globally, compelling drug manufacturers to accelerate production to satisfy the global need. The FDA initiated the COVID-19 Treatment Acceleration Program (CTAP), an emergency program developed to expedite the creation and availability of potential COVID-19 treatments.

Get Your COVID-19 Current Therapy Market Report Here:
https://www.thebusinessresearchcompany.com/report/coronavirus-current-therapy-global-market-report

What growth opportunities are expected to drive the covid-19 current therapy market's CAGR through 2034?
In recent years, the market size for COVID-19 current therapy has experienced a significant downturn. It is projected to fall from "$5.87 billion in 2024 to $2.35 billion in 2025", decreasing at a compound annual growth rate (CAGR) of -60.0%. Factors such as the shortage of effective treatment options, inconsistencies in treatment success, interruptions in the supply chain, rapidly growing scientific research, and the onset of new variants are responsible for the market's historic decrease.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp

What are the emerging trends shaping the future of the covid-19 current therapy market?
The employment of Convalescent Plasma Therapy is being explored as an innovative treatment for patients with COVID-19. Convalescent plasma, or CP, is the term used for the blood plasma extracted from individuals who have successfully recovered from a disease. As a subset of passive antibody therapy, convalescent plasma therapy involves using this plasma, replete with disease-fighting antibodies, and administering it to severely ill patients in order to alleviate symptoms and suppress the lethalness of the disease in question. The blood plasma from patients who have beaten COVID-19 is considered rich in antibodies capable of combating the virus. In line with the FDA's directives, Convalescent Plasma Therapy should be treated as a product for experimental use during a public health crisis. As per data, around 2,004 locations were following a uniform expanded access protocol sanctioned by the US FDA, with approximately 7,774 patients enlisted, and 3,809 of whom had received a transfusion of convalescent plasma. If substantiated by enough reliable data, the experimental use of Convalescent Plasma Therapy is expected to gain more traction.

Which growth-oriented segments of the covid-19 current therapy market are leading the industry's development?
The COVID-19 current therapy market covered in this report is segmented -

1) By Drug Type: Antiviral, Monoclonal Antibodies, Corticosteroid, Supplements, Antimalarial, Interferons And Interleukin Inhibitors, Other Anti-Infective Drugs, Others
2) By Route Of Administration: Oral, Intravenous
3) By End-User: Hospitals, Clinics, Home Care, Others

Subsegments:
1) By Antiviral: Remdesivir, Oseltamivir, Favipiravir, Nirmatrelvir Or ritonavir (Paxlovid)
2) By Monoclonal Antibodies: Bamlanivimab, Casirivimab Or Imdevimab (REGEN-COV), Sotrovimab, Etesevimab
3) By Corticosteroid: Dexamethasone, Hydrocortisone, Prednisone
4) By Supplements: Vitamin D, Vitamin C, Zinc, Quercetin
5) By Antimalarial: Hydroxychloroquine, Chloroquine
6) By Interferons and Interleukin Inhibitors: Interferon beta-1a, Interleukin-6 inhibitors
7) By Other Anti-Infective Drugs: Antibiotics, Antifungal agents
8) By Others: Other experimental therapies, Alternative treatments not categorized above

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3247

What regions are leading the charge in the covid-19 current therapy market?
North America is the largest region in the COVID-19 current therapy market in 2024. Middle East is expected to be the fastest-growing region in the global COVID-19 current therapy market share during the forecast period. The regions covered in the COVID-19 current therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the covid-19 current therapy market?
Major companies operating in the COVID-19 current therapy market include Gilead Sciences, Inc., Ipca Laboratories Limited, Zydus Cadila, Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, AbbVie, Glenmark Pharmaceuticals Limited, Eli Lilly and Company, Wallace Pharmaceuticals, Inc., Mylab Discovery Solutions, Kalbe Farma, He Qi Group Foundation, Beijing Jinwofu Bioengineering Technology Company, Zhejiang Orient Gene Biotech Co. Ltd, Transasia Bio Medicals, Vanguard Diagnostics, HLL Lifecare Limited, Voxtur Bio Ltd, Biocryst Pharma, Clover Biopharmaceuticals, Inovio Pharmaceuticals, Inc., LAB-CARE Diagnostics, ImmunoScience, CPC Diagnostics, Sysmex Corporation, Atomo Diagnostics, Cellmid Limited, Moderna Therapeutics, Novavax, Bravovax, Ascletis Pharma, Altimmune, Hunan Lituo Biotechnology, Hangzhou Biotest Biotech, AmonMed Biotechnology, Getein Biotech, Beijing Tigsun Diagnostics, Vivacheck Lab, Seegene, SD Biosensor, Fujirebio, Siemens Healthcare Pte. Ltd., Senova, LetsGetChecked, Omega Diagnostics, Abingdon Health, Babylon, Motologic, F. Hoffmann-La Roche Ltd., Novacyt Group, AstraZeneca, Pfizer, Zentiva, Boehringer Ingelheim, GlaxoSmithKline, Merck & Co., Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi, Amgen and AdaptiveBiotechnologies, BioNtech, Cytodyn, Heat biologics, Johnson&Johnson, Takeda pharmaceuticals, Vaxart, Vir Biotechnology, Victory Square Health, Abbott Molecular Inc., ACRO Biotech, Advagen Biotech Ltd, BD, Boditech Med, Inc., Cellex Inc., CerTest Biotec, S.L., Hi Technologies, BATM, BioMedomics Quant Lease, CapeBio, Astel Diagnostics, Canary Health Technologies, Thermo Fisher Scientific

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=3247&type=smp

What Is Covered In The COVID-19 Current Therapy Global Market Report?

•Market Size Forecast: Examine the covid-19 current therapy market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the covid-19 current therapy market for a structured understanding.
•Key Players Overview: Analyze major players in the covid-19 current therapy market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the covid-19 current therapy market.
•Segment Contributions: Evaluate how different segments drive overall growth in the covid-19 current therapy market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the covid-19 current therapy market.
•Industry Challenges: Identify potential risks and obstacles affecting the covid-19 current therapy market.
•Competitive Landscape: Review strategic developments in the covid-19 current therapy market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.